Understanding tumor lysis syndrome
Compliance with ethical standards
Conflicts of interest
L Zafrani has received a research grant from Jazz Pharma. Dr. Darmon reports grants from MSD, personal fees from Gilead-Kite, personal fees from Astelas, outside the submitted work; Dr. CANET reports personal fees from GILEAD, outside the submitted work.
- 2.Darmon M, Vincent F, Camous L et al (2013) Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique. Br J Haematol 162:489–497CrossRefGoogle Scholar
- 11.Cortes J, Moore JO, Maziarz RT et al (2010) Control of Plasma Uric acid in adults at risk for tumor lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone—results of a multicenter phase III study. J Clin Oncol 28:4207–4213CrossRefGoogle Scholar
- 15.Agha-Razii M, Amyot SL, Pichette V et al (2000) Continuous veno-venous hemodiafiltration for the treatment of spontaneous tumor lysis syndrome complicated by acute renal failure and severe hyperuricemia. Clin Nephrol 54:59–63Google Scholar